To evaluate whether rifaximin could prolong overall survival (OS) and reduce the risks of various cirrhotic complications in patients experiencing hepatic encephalopathy

Trial Profile

To evaluate whether rifaximin could prolong overall survival (OS) and reduce the risks of various cirrhotic complications in patients experiencing hepatic encephalopathy

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2017 Results published in the Alimentary Pharmacology and Therapeutics
    • 10 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top